Medical Innovations Group

medicalinnovations.co.uk

Medical Innovations Group designs and manufactures medical equipment for a diverse range of markets - from Hospitals and Emergency Services to the Armed Forces. All products are developed under tight quality-controlled conditions and have undergone extensive testing and trials. As a result, they meet the highest possible quality and regulatory standards.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

LIGHT BIO PARTNERS WITH GINKGO BIOWORKS TO OPTIMIZE THE BRIGHTNESS OF GLOWING PLANTS THROUGH BIOLUMINESCENCE ENGINEERING

Light Bio | April 18, 2022

news image

Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants. The scientists at Light Bio have discovered a new...

Read More

Industrial Impact

CELYAD ONCOLOGY ANNOUNCES FDA LIFTS CLINICAL HOLD OF CYAD-101-002 PHASE 1B TRIAL

Celyad Oncology | August 01, 2022

news image

Celyad Oncology SA a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 Phase 1b trial after the Company made changes to the eligibility criteria for the trial. “We are pleased that the FDA lifted the clinical hold on this trial. We remain confident in the p...

Read More

AI, Diagnostics

GENOMIC VISION ANNOUNCES LAUNCH OF FIBERSMART

Genomic Vision | March 08, 2023

news image

On March 7, 2023, Genomic Vision, a leading biotech company that develops products and services for the analysis and control of genome changes, launched FiberSmart®, an AI-based technology for automating the quantification and detection of fluorescent signals on combed DNA molecules. Initially available for the analysis of Replication Combing Assays (RCA), Genomic Vision's proprietary method for directly visualizing DNA replication kinetics at the single molecule level. ...

Read More

Cell and Gene Therapy, Diagnostics

VERTEX AND CRISPR THERAPEUTICS ANNOUNCE A LICENSING AGREEMENT TO HASTEN THE DEVELOPMENT OF HYPOIMMUNE CELL THERAPIES FOR TYPE 1 DIABETES

Businesswire | March 28, 2023

news image

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). “We have multiple programs in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune program, in preclinic...

Read More
news image

Medical

LIGHT BIO PARTNERS WITH GINKGO BIOWORKS TO OPTIMIZE THE BRIGHTNESS OF GLOWING PLANTS THROUGH BIOLUMINESCENCE ENGINEERING

Light Bio | April 18, 2022

Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants. The scientists at Light Bio have discovered a new...

Read More
news image

Industrial Impact

CELYAD ONCOLOGY ANNOUNCES FDA LIFTS CLINICAL HOLD OF CYAD-101-002 PHASE 1B TRIAL

Celyad Oncology | August 01, 2022

Celyad Oncology SA a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 Phase 1b trial after the Company made changes to the eligibility criteria for the trial. “We are pleased that the FDA lifted the clinical hold on this trial. We remain confident in the p...

Read More
news image

AI, Diagnostics

GENOMIC VISION ANNOUNCES LAUNCH OF FIBERSMART

Genomic Vision | March 08, 2023

On March 7, 2023, Genomic Vision, a leading biotech company that develops products and services for the analysis and control of genome changes, launched FiberSmart®, an AI-based technology for automating the quantification and detection of fluorescent signals on combed DNA molecules. Initially available for the analysis of Replication Combing Assays (RCA), Genomic Vision's proprietary method for directly visualizing DNA replication kinetics at the single molecule level. ...

Read More
news image

Cell and Gene Therapy, Diagnostics

VERTEX AND CRISPR THERAPEUTICS ANNOUNCE A LICENSING AGREEMENT TO HASTEN THE DEVELOPMENT OF HYPOIMMUNE CELL THERAPIES FOR TYPE 1 DIABETES

Businesswire | March 28, 2023

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). “We have multiple programs in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune program, in preclinic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us